GlassScriptPhysician profile
Michael J Huang
NPI 1295962397
$5,261.92
in general payments reported to CMS, 2019-2025
33 companies · $2,462 in 2025
The $2,462 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $313 · 2020: $44.62 · 2021: $149 · 2022: $310 · 2023: $703 · 2024: $1,280 · 2025: $2,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,411 · Education: $33.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,410.72 |
| Education | $33.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $693.04 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Abbvie INC. | $657.81 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $570.71 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $463.53 | 2022-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $412.27 | 2021-2025 | Vemlidy, Livdelzi |
| Pfizer INC. | $367.17 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $284.52 | 2022-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $267.17 | 2023 | Zeposia |
| Qol Medical, LLC | $170.64 | 2023-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $149.38 | 2022-2025 | Ibsrela |
| Organon LLC | $148.21 | 2024-2025 | Hadlima, Renflexis, Nexplanon |
| Alnylam Pharmaceuticals INC. | $125.35 | 2022-2025 | Givlaari |
| Celgene Corporation | $90.26 | 2022-2023 | Zeposia |
| Neuraxis, INC. | $87.50 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $82.97 | 2023-2025 | Iqirvo, Bylvay |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $75.28 | 2024-2025 | |
| Madrigal Pharmaceuticals | $74.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $74.21 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $67.06 | 2019-2025 | Rebyota |
| Lilly USA, LLC | $55.21 | 2024 | Omvoh, Zepbound |
| Ironwood Pharmaceuticals, INC | $54.00 | 2021-2024 | |
| Laborie Medical Technologies Corp. | $36.92 | 2025 | Alphaone |
| Celltrion USA INC. | $33.24 | 2024-2025 | Zymfentra, Vegzelma |
| Braintree Laboratories, INC. | $32.81 | 2020-2025 | Sutab |
| Merck Sharp & Dohme LLC | $29.34 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $28.28 | 2025 | Pyrukynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.91 | 2024 | Cyltezo |
| Fresenius Kabi USA, LLC | $26.07 | 2023 | Idacio |
| Blueprint Medicines Corporation | $21.67 | 2025 | Ayvakit |
| Novo Nordisk INC | $21.59 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $18.89 | 2025 | Zenpep |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 | |
| Phathom Pharmaceuticals, INC. | $4.99 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.